RxDoctor Payments Data

Benjamin Wagner

Medical · Amherst, NYNPI 1447591565

Payments from drug & device makers

$12,862in general payments, 2019–2025

Across 758 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Lundbeck LLC$1K
  • Neurocrine Biosciences, Inc.$1K
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$12,66898%
  • Education$1942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,862 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$60,159
Medicare patients
162
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate38$276,653
IngrezzaValbenazine Tosylate18$146,283
NuedextaDextromethorphan Hbr/Quinidine62$110,124
VraylarCariprazine Hcl73$104,288
Abilify MaintenaAripiprazole31$84,657
TrintellixVortioxetine Hydrobromide112$79,624
CaplytaLumateperone Tosylate24$43,875
RexultiBrexpiprazole27$40,156
AristadaAripiprazole Lauroxil13$37,755
Lurasidone Hcl83$31,336
Clozapine OdtClozapine30$30,850
Aripiprazole726$26,841
FanaptIloperidone14$25,878
LybalviOlanzapine/Samidorphan Malate16$24,555
Chlorpromazine Hcl25$19,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$132$276,65338 claims
Neurocrine Biosciences, Inc.Ingrezza$1,059$146,28318 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$1,222$124,81358 claims
AbbVieVraylar, Lexapro$1,556$118,310104 claims
Avanir Pharmaceuticals, Inc.Nuedexta$231$110,12462 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$421$79,624112 claims
Alkermes, Inc.Aristada, Lybalvi$697$62,31029 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,340$43,87524 claims
Vanda Pharmaceuticals Inc.Fanapt$550$25,87814 claims
Eisai Inc.Dayvigo$74$8,22724 claims
MerckBelsomra$21$6,64315 claims
Johnson & JohnsonRisperdal$716$3,39712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.

Other medical in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →